REG - Renalytix PLC - Admission of Shares & Total Voting Rights

RenalytixAnnouncement

08/10/2024 14:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241008:nRSH4004Ha&default-theme=true

RNS Number : 4004H  Renalytix PLC  08 October 2024

Renalytix plc

("Renalytix" or the "Company")

 

Admission of Shares & Total Voting Rights

 

Renalytix (AIM: RENX), an artificial intelligence-enabled in vitro diagnostics
company, focused on optimizing clinical management of kidney disease to drive
improved patient outcomes and advance value-based care, announces that,
further to the Company's announcement on 1 October 2024, application has been
made to the London Stock Exchange for the admission of the first tranche of
new ordinary shares of £0.0025 each ("Ordinary Shares") (the "EIS/VCT Placing
Shares") to trading on AIM. The number of Ordinary Shares in this tranche is
24,007,773 instead of the previously announced 23,174,440, due to a request
for additional EIS/VCT Qualifying Shares. Admission of these new Ordinary
Shares is expected to take place at or around 8.00 a.m. UK time tomorrow, 9
October 2024.

 

There is no change to the total fundraise amount or shares to be issued, only
the mix between First and Second Admission.

 

Total Voting Rights

 

Following the issue of the EIS/VCT Placing Shares, the issued share capital of
the Company will consist of 189,933,286 Ordinary Shares. Each Ordinary
Share carries one vote and there are no shares held in treasury. Therefore,
the total number of voting rights in the Company following admission tomorrow
will be 189,933,286 and this figure may be used by shareholders as the
denominator for the calculations by which they can determine if they are
required to notify their interest in, or a change of their interest in the
Company under the Financial Conduct Authority's Disclosure and Transparency
Rules.

 

Further Admission, Settlement and Dealings

 

Subject to the Resolutions being passed at the General Meeting on 31 October
2024, application will be made to the London Stock Exchange ("LSE") for
admission of the 68,766,149 Non-EIS/VCT Placing Shares, the 38,387,634
Subscription Shares and 36,550,543 Conversion Shares to trading on AIM. It is
expected that Second Admission will take place at or around 8.00 a.m. UK time
on 1 November 2024 and that dealings on AIM will commence at the same time.

 

Following Second Admission, the Company will have 333,637,612 Ordinary Shares
in issue.

 

Capitalised terms not defined in this announcement have the meanings given to
them in the Company's announcement dated 1 October 2024.

 

The person responsible for making this announcement on behalf of the Company
is James McCullogh, Chief Executive Officer.

 

For further information, please contact:

 

 Renalytix Plc                                                            www.renalytix.com (http://www.renalytix.com)

 James McCullough, CEO                                                    Via Walbrook PR

 Stifel (Nominated Adviser and Joint Broker)                              Tel: 020 7710 7600

 Nicholas Moore / Nick Harland / Ben Good

 Oberon Capital (Joint Broker)                                            Tel: 020 3179 5300

 Mike Seabrook / Nick Lovering / Jessica Cave

 Walbrook PR Limited             Tel: 020 7933 8780 or renalytix@walbrookpr.com

                               (mailto:renalytix@walbrookpr.com)
 Paul McManus / Alice Woodings

                                 Mob: 07980 541 893 / 07407 804 654

 CapComm Partners                Tel: 415-389-6400 or investors@renalytix.com (mailto:investors@renalytix.com)

 Peter DeNardo

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ALSFLFEFILLTIIS